Log in to save to my catalogue

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development fo...

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development fo...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3337408

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

About this item

Full title

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Publisher

Berlin/Heidelberg: Springer-Verlag

Journal title

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer-Verlag

More information

Scope and Contents

Contents

Purpose
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a stable thioether linker. To characterize the pharmacokinetics (PK) of T-DM1 in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, data fro...

Alternative Titles

Full title

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3337408

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3337408

Other Identifiers

ISSN

0344-5704

E-ISSN

1432-0843

DOI

10.1007/s00280-011-1817-3

How to access this item